Intervention Review

You have free access to this content

Oral antiplatelet therapy for acute ischaemic stroke

  1. Peter AG Sandercock1,*,
  2. Carl Counsell2,
  3. Mei-Chiun Tseng3,
  4. Emanuela Cecconi1

Editorial Group: Cochrane Stroke Group

Published Online: 26 MAR 2014

Assessed as up-to-date: 24 OCT 2013

DOI: 10.1002/14651858.CD000029.pub3


How to Cite

Sandercock PAG, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD000029. DOI: 10.1002/14651858.CD000029.pub3.

Author Information

  1. 1

    University of Edinburgh, Division of Clinical Neurosciences, Edinburgh, UK

  2. 2

    University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK

  3. 3

    National Sun Yat-Sen University, Department of Business Management, Kaohsiung, Taiwan, China

*Peter AG Sandercock, Division of Clinical Neurosciences, University of Edinburgh, Neurosciences Trials Unit, Bramwell Dott Building, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK. peter.sandercock@ed.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 26 MAR 2014

SEARCH

[Figure 1]
Figure 1. Flow diagram.
[Figure 2]
Figure 2. Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.1 Death or dependence at end of follow-up.
[Figure 3]
Figure 3. Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.2 Deaths from all causes during treatment period.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 1 Death or dependence at end of follow-up.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 2 Deaths from all causes during treatment period.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 3 Deaths from all causes during follow-up.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 4 Deep venous thrombosis during treatment period.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 5 Pulmonary embolism during treatment period.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 6 Recurrent ischaemic/unknown stroke during treatment period.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 7 Symptomatic intracranial haemorrhage during treatment period.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 8 Any recurrent stroke/intracranial haemorrhage during treatment period.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 9 Major extracranial haemorrhage during treatment period.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 10 Complete recovery from stroke (post hoc).